Asthma is a common chronic inflammatory disease of the airways which remains uncontrolled despite current therapy for many patients. Asthma is characterised by fluctuating symptoms which include coughing, chest tightness, wheezing and shortness of breath. Genetic and environmental factors contribute to asthma and there are numerous stimuli that can trigger asthma, both atopic (allergic) and non-atopic (non-allergic).
Asthma has no cure, so long-term prevention focuses on avoiding known triggers. Asthma is classified by the frequency and extent of symptoms, the forced expiratory volume in one second (FEV1) and peak expiratory flow rate.
Treatment options for asthma include inhaled corticosteroids (ICS) which can be used alongside long-acting beta 2 agonists (LABA) or antileukotriene agents if the symptoms persist. Short-acting β2-agonist (SABA) as the only treatment is no longer recommended following strong evidence that this increases the risk of severe exacerbations and asthma-related death. Adding any ICS significantly reduces this risk.
To find out more about moderate to severe asthma, visit our dedicated Learning Zone, which contains further information on the causes of asthma and the Global Initiative for Asthma (GINA) recommendations for management.
Featured Learning Zones
The Respiratory Care Learning Zone contains essential information on Inhaled Therapies in Asthma and COPD and its Management. The Learning Zone also has an Educational Resources section which features slide kits, congress news and webinars and videos relevant to asthma and COPD.
Related news and insights
A pivotal Phase III trial of Dupixent (dupilumab) met its primary and all key secondary endpoints in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma.
GlaxoSmithKline plc and Innoviva, Inc. announced the FDA has approved a new indication for Trelegy Ellipta (fluticasone furoate / umeclidinium / vilanterol ‘FF/UMEC/VI’) for the treatment of asthma in patients aged 18 years and older adding to its current license for use in patients with chronic obstructive pulmonary disease (COPD).
Novartis announced that high-dose, once-daily Enerzair Breezhaler (indacaterol acetate, glycopyrronium bromide and mometasone furoate [IND/GLY/MF]) significantly reduces both moderate-or-severe and severe asthma exacerbation rates in patients whose asthma is uncontrolled on medium- or high-dose long-acting beta2-agonist (LABA)/inhaled corticosteroids (ICS), when compared with a once-daily medium-dose of the same treatment.
You may be interested in...
The Union-North America Region (NAR) is the regional arm of the International Union against Tuberculosis and Lung Disease (The Union), a global public health organization with the vision to provide health solutions to the poor.
28th Conference On Retrovirus And Opportunistic Infections 2021
CROI is the preeminent meeting in the world and attracts more than 4,000 research leaders from nearly 90 countries and nearly half of CROI attendees come from outside the United States. In recent years, more than 1000 abstracts have been selected for presentation at CROI.